FDA Approves TWIRLA — Agile Therapeutics, Inc.

Agile Therapeutics, Inc. secured FDA approval for Twirla (levonorgestrel/ethinyl estradiol) transdermal gel, positioning the company to compete in a crowded contraceptive market by offering patients a distinct OTC-style ease of administration. This approval is expected to bolster the company's commercial pipeline, though investors will closely monitor the product's ability to secure a significant market share against dominant oral contraceptive forms.